8-K: PepGen Appoints Joseph Vittiglio as Chief Business and Legal Officer

PepGen Inc. announced the appointment of Joseph Vittiglio, Esq., as its new Chief Business and Legal Officer, bringing over two decades of executive leadership experience.

Summary

• PepGen Inc. appointed Joseph Vittiglio, Esq., as Chief Business and Legal Officer, effective December 8, 2025.
• Mr. Vittiglio brings over two decades of executive leadership experience across legal, compliance, corporate development, and corporate governance within public biotechnology companies.
• His previous roles include Chief Business and Legal Officer and Corporate Secretary at bluebird bio, where he supported the approval and launch of three U.S. gene therapy products and completed over $400 million in financings.
• He also served as Chief Business and Legal Officer at Finch Therapeutics, guiding its IPO and building public-company governance, and at AMAG Pharmaceuticals, supporting major corporate transactions and multiple product launches for a commercial organization generating over $400 million annually.
• The company anticipates 2026 readouts from the 5 mg/kg and 10 mg/kg cohorts in its FREEDOM2-EDODM1 multiple ascending dose study in DM1 patients.

Sentiment

Score: 8

Explanation: The appointment of a highly experienced Chief Business and Legal Officer with a strong track record in biotech, including product launches and significant financings, is a very positive development for PepGen, strengthening its executive team and strategic capabilities.

Positives

• Appointment of a highly experienced executive, Joseph Vittiglio, with over two decades of leadership in legal, compliance, corporate development, and corporate governance.
• Mr. Vittiglio has a proven track record in guiding companies through complex transactions, regulatory milestones, financings, product launches, and strategic partnerships.
• His experience includes supporting the approval and launch of three U.S. gene therapy products and completing over $400 million in financings at bluebird bio.
• Strengthens PepGen's executive leadership team as the company advances its PGN-EDODM1 program.

Future Outlook

PepGen anticipates 2026 readouts from the 5 mg/kg and 10 mg/kg cohorts in its FREEDOM2-EDODM1 multiple ascending dose study in DM1 patients, indicating continued progress in its clinical programs.

Management Comments

• "Joe is a deeply experienced legal and business leader with a proven track record guiding companies through complex transactions, regulatory milestones, financings, product launches, and strategic partnerships."
• "We are excited to welcome him to PepGen’s executive leadership team as we continue to make significant progress advancing our PGN-EDODM1 program and prepare for the anticipated 2026 readouts from the 5 mg/kg and 10 mg/kg cohorts in our FREEDOM2-EDODM1 multiple ascending dose study in DM1 patients."

Industry Context

The appointment of a seasoned executive with extensive experience in gene therapy product launches and significant financings is a strategic move for a clinical-stage biotechnology company like PepGen, operating in the competitive and highly regulated neuromuscular and neurological disease space. This strengthens the company's capabilities as it progresses its oligonucleotide therapies through clinical development and towards potential commercialization, aligning with broader industry trends of robust corporate development and legal expertise for emerging biotechs.

Comparison to Industry Standards

• Mr. Vittiglio's experience at bluebird bio, where he supported the approval and launch of three U.S. gene therapy products, demonstrates a level of expertise comparable to top-tier biotechnology executives involved in successful commercialization efforts.
• His involvement in over $400 million in financings at bluebird bio and guiding Finch Therapeutics' IPO indicates a strong background in capital markets, which is crucial for clinical-stage companies in the biotech sector.
• His prior role at AMAG Pharmaceuticals, a commercial organization generating over $400 million annually, suggests experience in scaling and managing legal and business development for a significant revenue-generating entity, a benchmark for successful biotech growth.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Likely positive impact due to the addition of a highly experienced executive who can guide the company through complex transactions, regulatory milestones, and strategic partnerships, potentially enhancing long-term value.
• Employees: Strengthens the executive team, potentially providing clearer strategic direction and leadership.
• Customers (future patients): The appointment supports the company's efforts to advance its pipeline, which could ultimately lead to new treatments for severe neuromuscular and neurological diseases.

Next Steps

• Continue advancing the PGN-EDODM1 program.
• Prepare for anticipated 2026 readouts from the 5 mg/kg and 10 mg/kg cohorts in the FREEDOM2-EDODM1 multiple ascending dose study in DM1 patients.

Key Dates

Keywords

PepGen, biotechnology, oligonucleotide therapies, neuromuscular diseases, neurological diseases, executive appointment, Chief Business and Legal Officer, corporate governance, clinical-stage, gene therapy